trending Market Intelligence /marketintelligence/en/news-insights/trending/vlcBpF0WDejKN0CAFL7u3w2 content esgSubNav
In This List

GlaxoSmithKline seeks FDA approval for single-dose malaria treatment

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


GlaxoSmithKline seeks FDA approval for single-dose malaria treatment

GlaxoSmithKline plc and Medicines for Malaria Venture submitted a new drug application to the U.S. Food and Drug Administration seeking approval for a malaria treatment, tafenoquine.

Single-dose tafenoquine is meant to prevent relapse of Plasmodium vivax malaria for patients over 16 years of age.

If approved, tafenoquine would be the first new medicine in more than 60 years that is intended to keep the strain of malaria from coming back. It was originally synthesized by scientists at the Walter Reed Army Institute of Research in 1978, and GSK entered a collaboration with Medicines for Malaria to develop it in 2008.

The submission includes phase 3 data studies conducted by GlaxoSmithKline in partnership with Medicines for Malaria. The FDA granted tafenoquine the breakthrough therapy designation in 2013.

GlaxoSmithKline plans to submit regulatory filings for the treatment in other countries in 2017 and 2018.